Mizuho analyst Irina Koffler says Jazz Pharmaceuticals last night provided a commercial update on Sunosi ahead of its July 8 launch with lower pricing and higher discounting than she previously modeled. The company views its market opportunity as consisting of 165,000 patients in narcolepsy, and another 12M patients with sleep apnea, Koffler tells investors in a research note. Wholesale acquisition cost pricing has been set at $660 per month, below the analyst's $900 per month estimate. Koffler is now more conservative on Sunosi following last night's update and she reiterates a Neutral rating on Jazz shares with a $148 price target.